Medicago Inc.
TSX VENTURE : MDG

Medicago Inc.

May 16, 2008 08:00 ET

Medicago Announces Poster Presentation at the IDSA Seasonal and Pandemic Influenza 2008 Meeting

QUEBEC CITY, QUEBEC--(Marketwire - May 16, 2008) - Medicago Inc. (TSX VENTURE:MDG) (the "Company"), today announced that its abstract has been selected for poster presentation at the Infectious Diseases Society of America (IDSA) Seasonal and Pandemic Influenza 2008 meeting, held in Arlington, Virginia from May 18-20, 2008. Ms. Nathalie Charland, Product Portfolio manager, will present highlights of the Company's development of Influenza vaccines generated from plant-made Virus-Like Particles ("VLP") and the potential of its proprietary manufacturing technology to address global pandemic influenza supply challenges.

Poster Presentation: "An innovative VLP-based technology to respond to global influenza needs", Charland N., Landry N., Trepanier S., Guay J.M., D'Aoust M.A., Dargis M. and Vezina L.P., Sunday May 18, noon to 1:30 p.m., Crystal Gateway Marriott, Arlington Ballroom, Salon 3

The IDSA Seasonal and Pandemic Influenza 2008 meeting focuses on recent progress in basic and clinical research regarding preparedness for outbreaks of influenza. The meeting will cover timely topics such as Meeting Global Vaccine Demand Global, Global Status of H5N1 Influenza and Pandemic Influenza Planning, amongst many others. Attendees and speakers will include members of the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), state and local health officials, policymakers and other stakeholders. For more information, please visit www.idsociety.org.

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

Contact Information

  • Medicago, Inc.
    Andy Sheldon
    President and CEO
    418-658-9393
    or
    Investor relations
    The Equicom Group Inc.
    Arianna Vanin
    514-844-4680
    avanin@equicomgroup.com